EP Patent

EP4132932A4 — Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof

Assigned to Syndax Pharmaceuticals Inc · Expires 2024-04-17 · 2y expired

What this patent protects

Patent listed against revumenib-citrate.

Drugs covered by this patent

revumenib-citrate (REVUMENIB CITRATE)

Patent Metadata

Patent number: EP4132932A4
Jurisdiction: EP
Classification: —
Expires: 2024-04-17
Drug substance claim: No
Drug product claim: No
Assignee: Syndax Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.